Levofloxacin can be used for travel-related infections such as travelers’ diarrhea caused by susceptible bacteria. Carry the medication in its original packaging, keep it at room temperature, and ensure you have a prescription copy for customs if required.
Moderate alcohol consumption does not directly interact with levofloxacin, but excessive intake may worsen gastrointestinal side effects like nausea or dizziness. It is advisable to limit alcohol until the infection has resolved.
In the UK, a 500 mg levofloxacin tablet typically bears the imprint “LEVO 500” on one side and “M N” on the other, though imprint codes can vary by manufacturer. Always verify the appearance against the pharmacist’s dispensing label.
Levofloxacin is an antibiotic and is not screened for in standard occupational drug testing panels. However, if a laboratory uses a comprehensive assay, the presence of the drug may be noted; it does not constitute a positive result for illicit substances.
Both agents are effective against common CAP pathogens. Levofloxacin offers broader gram-negative coverage and a single-dose regimen, while azithromycin has a shorter course and fewer concerns about tendon toxicity. Choice depends on patient risk factors, local resistance patterns, and clinician judgment.
Calcium can bind levofloxacin in the gut and markedly reduce its absorption. If you wish to consume calcium-fortified beverages, take them at least two hours before or after the antibiotic dose.
Stop the medication immediately and seek medical attention. Early cessation reduces the risk of complete tendon rupture. Your clinician may prescribe an alternative antibiotic and advise imaging if needed.
Yes. Generic levofloxacin tablets must meet the MHRA’s strict bioequivalence standards, ensuring they deliver the same amount of active drug to the bloodstream as the reference product.
Levofloxacin’s renal elimination may be temporarily reduced after contrast administration. Discuss with your physician; they may advise a short interval between the two procedures or a temporary dose adjustment.
Tablets remain stable until the printed expiry date provided the container is kept tightly closed, stored at room temperature, and protected from moisture. Do not use tablets past this date.
Levofloxacin is a broad-spectrum fluoroquinolone antibiotic that is prescribed across the United Kingdom for a variety of bacterial infections. It is available as oral tablets (pill) in strengths of 250 mg, 500 mg, and 750 mg. The medication is classified as a prescription-only (POM) product and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Levofloxacin works by interfering with bacterial DNA synthesis, which ultimately stops bacterial growth and leads to eradication of the infection.
Levofloxacin belongs to the fluoroquinolone class. Its primary mechanism is inhibition of two essential bacterial enzymes:
By binding to these enzymes, levofloxacin prevents the unwinding and replication of bacterial DNA. This action is bactericidal (it kills bacteria rather than merely inhibiting growth). The drug is absorbed well after oral administration, reaching peak plasma concentrations within 1-2 hours. It is widely distributed in tissues, including the lungs, sinuses, prostate, and urinary tract, which explains its effectiveness in treating infections at these sites. Levofloxacin is primarily eliminated unchanged by the kidneys; consequently, renal function influences dosing.
Levofloxacin is approved by the MHRA for the following adult indications:
These approvals are based on clinical trials that demonstrated non-inferior efficacy compared with other standard antibiotics, while offering once-daily dosing convenience.
Levofloxacin has been investigated for several off-label indications. Where scientific evidence exists, it is summarized below; each use remains outside the formal MHRA licence and must be considered only under specialist supervision.
| Off-label indication | Evidence summary | Regulatory note | |||| | Prophylaxis of bacterial infection in neutropenic cancer patients | Randomised controlled trials have shown reduced febrile episodes when levofloxacin is given prophylactically to patients with prolonged neutropenia. | Not approved for prophylaxis in the UK; requires oncology specialist oversight. | | Chronic bacterial prostatitis | Small open-label studies suggest symptom improvement after extended (≥4 weeks) therapy, but data are limited. | Use is off-label; risk-benefit assessment essential. | | Acute bacterial otitis media (adults) | Limited comparative data indicate similar cure rates to amoxicillin/clavulanic acid. | Not licensed for otitis media; clinicians may consider when first-line agents are unsuitable. |
Disclaimer: Off-label use must be guided by a qualified healthcare professional who can assess individual risk, monitor for adverse effects, and ensure appropriate dosing.
| Infection | Typical Dose* | Duration | |||| | Acute bacterial sinusitis | 500 mg once daily | 5 - 7 days | | CAP (moderate severity) | 750 mg once daily (first dose may be 500 mg, then 750 mg) | 5 - 7 days | | Uncomplicated UTI | 250 mg once daily | 3 - 5 days | | cUTI or pyelonephritis | 750 mg once daily | 7 - 14 days | | ABSSSI | 750 mg once daily | 5 - 10 days | | Acute prostatitis | 500 mg twice daily (or 750 mg once daily) | 10 - 14 days |
*Doses refer to tablet strengths listed (250 mg, 500 mg, 750 mg). Exact regimen must be prescribed by a clinician.
If a dose is missed and the next scheduled dose is more than 12 hours away, take the missed dose as soon as remembered. Do not double the next dose.
Symptoms of overdose may include nausea, vomiting, dizziness, and seizures. Immediate medical attention is required. Supportive care, including gastric lavage and activated charcoal, may be administered in a hospital setting. No specific antidote exists.
Levofloxacin does not typically require tapering. However, abrupt cessation after prolonged therapy for certain infections (e.g., prostatitis) should be discussed with a prescriber to ensure infection control.
This article provides educational information about levofloxacin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
